Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KRYS NASDAQ:PCVX NASDAQ:PHVS NASDAQ:PTCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKRYSKrystal Biotech$144.45+0.1%$146.80$122.80▼$207.84$4.18B0.66326,752 shs238,079 shsPCVXVaxcyte$32.35-2.1%$33.18$27.66▼$121.06$4.20B1.041.75 million shs973,181 shsPHVSPharvaris$23.37-0.5%$21.79$11.51▼$26.33$1.22B-2.884,001 shs23,694 shsPTCTPTC Therapeutics$61.04+0.1%$50.03$33.19▼$62.18$4.84B0.531.10 million shs1.21 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKRYSKrystal Biotech+5.02%-3.60%+0.52%+5.32%-27.38%PCVXVaxcyte+3.31%+2.83%+10.20%-4.34%-70.89%PHVSPharvaris+1.08%+6.92%+11.43%+40.72%+12.01%PTCTPTC Therapeutics+4.51%+5.09%+34.66%+18.92%+88.91%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKRYSKrystal Biotech$144.45+0.1%$146.80$122.80▼$207.84$4.18B0.66326,752 shs238,079 shsPCVXVaxcyte$32.35-2.1%$33.18$27.66▼$121.06$4.20B1.041.75 million shs973,181 shsPHVSPharvaris$23.37-0.5%$21.79$11.51▼$26.33$1.22B-2.884,001 shs23,694 shsPTCTPTC Therapeutics$61.04+0.1%$50.03$33.19▼$62.18$4.84B0.531.10 million shs1.21 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKRYSKrystal Biotech+5.02%-3.60%+0.52%+5.32%-27.38%PCVXVaxcyte+3.31%+2.83%+10.20%-4.34%-70.89%PHVSPharvaris+1.08%+6.92%+11.43%+40.72%+12.01%PTCTPTC Therapeutics+4.51%+5.09%+34.66%+18.92%+88.91%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKRYSKrystal Biotech 2.86Moderate Buy$209.0045.97% UpsidePCVXVaxcyte 3.00Buy$106.25229.76% UpsidePHVSPharvaris 2.80Moderate Buy$34.0042.68% UpsidePTCTPTC Therapeutics 2.53Moderate Buy$69.0013.04% UpsideCurrent Analyst Ratings BreakdownLatest PHVS, PTCT, KRYS, and PCVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025PCVXVaxcyteThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$38.009/3/2025PTCTPTC TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$118.008/22/2025KRYSKrystal BiotechChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$219.00 ➝ $216.008/22/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$240.008/20/2025PTCTPTC TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$79.00 ➝ $73.008/20/2025PTCTPTC TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$76.00 ➝ $71.008/20/2025PTCTPTC TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$82.00 ➝ $76.008/18/2025PHVSPharvarisZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/13/2025PHVSPharvarisJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$55.00 ➝ $52.008/8/2025PTCTPTC TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$70.008/8/2025PTCTPTC TherapeuticsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKRYSKrystal Biotech$290.52M14.26$4.83 per share29.64$32.90 per share4.35PCVXVaxcyteN/AN/AN/AN/A$26.52 per shareN/APHVSPharvarisN/AN/AN/AN/A$5.54 per shareN/APTCTPTC Therapeutics$806.78M6.01N/AN/A($14.24) per share-4.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKRYSKrystal Biotech$89.16M$4.9229.1014.20N/A40.85%15.21%13.81%11/3/2025 (Estimated)PCVXVaxcyte-$463.93M-$4.11N/AN/AN/AN/A-16.85%-15.92%11/4/2025 (Estimated)PHVSPharvaris-$145.24M-$3.36N/AN/AN/AN/A-69.09%-63.34%11/12/2025 (Estimated)PTCTPTC Therapeutics-$363.30M$6.978.75N/AN/A35.65%-106.31%30.61%11/6/2025 (Estimated)Latest PHVS, PTCT, KRYS, and PCVX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025PHVSPharvaris-$0.87-$0.94-$0.07-$0.94N/AN/A8/7/2025Q2 2025PTCTPTC Therapeutics-$1.07-$0.83+$0.24-$0.83$173.01 million$178.88 million8/6/2025Q2 2025PCVXVaxcyte-$1.12-$1.22-$0.10-$1.22N/AN/A8/4/2025Q2 2025KRYSKrystal Biotech$1.08$1.29+$0.21$1.29$95.42 million$96.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKRYSKrystal BiotechN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/APHVSPharvarisN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKRYSKrystal BiotechN/A9.689.33PCVXVaxcyteN/A11.1111.11PHVSPharvarisN/A8.338.33PTCTPTC TherapeuticsN/A3.623.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKRYSKrystal Biotech86.29%PCVXVaxcyte96.78%PHVSPharvarisN/APTCTPTC TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipKRYSKrystal Biotech13.70%PCVXVaxcyte3.10%PHVSPharvaris11.84%PTCTPTC Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKRYSKrystal Biotech21028.94 million24.98 millionOptionablePCVXVaxcyte160129.82 million125.80 millionOptionablePHVSPharvaris3052.29 million46.10 millionNot OptionablePTCTPTC Therapeutics1,41079.44 million75.07 millionOptionablePHVS, PTCT, KRYS, and PCVX HeadlinesRecent News About These CompaniesPTC Therapeutics (NASDAQ:PTCT) Director Sells $700,080.00 in StockSeptember 12 at 7:41 AM | insidertrades.comBayforest Capital Ltd Purchases New Shares in PTC Therapeutics, Inc. $PTCTSeptember 12 at 7:17 AM | marketbeat.comEric Pauwels Sells 39,850 Shares of PTC Therapeutics (NASDAQ:PTCT) StockSeptember 11 at 5:42 PM | marketbeat.comPTC Therapeutics, Inc. (PTCT) Launches SUFIANCE for PKUSeptember 11 at 1:28 PM | msn.comInsider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 39,850 Shares of StockSeptember 10 at 6:00 AM | insidertrades.comAQR Capital Management LLC Boosts Stake in PTC Therapeutics, Inc. $PTCTSeptember 10 at 3:53 AM | marketbeat.comCantor Fitzgerald Keeps Their Buy Rating on PTC Therapeutics (PTCT)September 8, 2025 | theglobeandmail.comPTC Therapeutics, Inc. (PTCT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 8, 2025 | seekingalpha.comPTC Therapeutics, Inc. $PTCT Shares Bought by Parkman Healthcare Partners LLCSeptember 8, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Receives $69.00 Consensus Price Target from AnalystsSeptember 8, 2025 | americanbankingnews.comPTC Therapeutics, Inc. (PTCT) Presents At Cantor Global Healthcare Conference 2025 TranscriptSeptember 7, 2025 | seekingalpha.comPTC Therapeutics, Inc. (PTCT) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptSeptember 7, 2025 | seekingalpha.comAdage Capital Partners GP L.L.C. Increases Stock Position in PTC Therapeutics, Inc. $PTCTSeptember 7, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Rating of "Moderate Buy" from AnalystsSeptember 7, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Receives "Overweight" Rating from Cantor FitzgeraldSeptember 5, 2025 | marketbeat.comPDT Partners LLC Has $2.06 Million Stock Position in PTC Therapeutics, Inc. $PTCTSeptember 5, 2025 | marketbeat.comCanada Pension Plan Investment Board Purchases 138,800 Shares of PTC Therapeutics, Inc. $PTCTSeptember 5, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Director Sells $83,600.05 in StockSeptember 4, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Stock Price Up 6.1% - Should You Buy?September 4, 2025 | marketbeat.comMPM Bioimpact LLC Has $22.42 Million Holdings in PTC Therapeutics, Inc. $PTCTSeptember 4, 2025 | marketbeat.comPalo Alto Investors LP Grows Stock Position in PTC Therapeutics, Inc. $PTCTSeptember 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePHVS, PTCT, KRYS, and PCVX Company DescriptionsKrystal Biotech NASDAQ:KRYS$144.62 +0.26 (+0.18%) As of 03:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Vaxcyte NASDAQ:PCVX$32.44 -0.62 (-1.86%) As of 03:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Pharvaris NASDAQ:PHVS$23.39 -0.11 (-0.45%) As of 03:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.PTC Therapeutics NASDAQ:PTCT$61.04 +0.08 (+0.13%) As of 03:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Intel's Silent Comeback: 3 Pillars the Market Is Overlooking Palantir’s Defense Partnerships Fuel Its Growth Story It May Be Time to Buy the Dip in Texas Instruments Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
